Warning letter
Balin, Martin S., MD, PhD: warning letter of Oct 10, 2012
FDA warning letter 353578 · Chicago District Office
Key facts
| Reference number | 353578 |
|---|---|
| Company | Balin, Martin S., MD, PhD |
| Subject | Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps) |
| Issue date | Oct 10, 2012 |
| Posted date | Oct 10, 2012 |
| Issuing office | Chicago District Office |
| Product type | Biologics |
| CFR sections cited | 1271, 1271.75, 1271.80, 1271.3(s), 1271.47(a), 1271.47(d), 1271.50(a), 1271.65(b), 1271.75(a), 1271.80(c), 1271.85(a), 1271.85(c) |
| Inspection city | Chicago |
| Inspection ZIP | 60654 |
| Inspection start date | Jun 20, 2012 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: